Therapeutic Advances In Rheumatoid Arthritis: A Comprehensive Review On The Role Of Dmards And Biologic Agents
Keywords:
Rheumatoid Arthritis, DMARDs, Biologics, Methotrexate, JAK Inhibitors, Autoimmune Disease, Targeted TherapyAbstract
Background: Rheumatoid arthritis (RA) is a long-lasting autoimmune inflammatory disease that causes gradual joint damage, pain, and disability. In recent years, treatment methods have shifted from simply managing symptoms to using targeted immune therapies with disease-modifying antirheumatic drugs (DMARDs) and biologics.
Objective: This review aims to evaluate recent advancements in RA treatment, focusing on conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), targeted synthetic disease-modifying antirheumatic drugs (tsDMARDs), and biologic disease-modifying antirheumatic drugs (bDMARDs). It will highlight their mechanisms, effectiveness, and safety.
Methods: A narrative literature review was conducted by searching PubMed, Scopus, and Google Scholar for articles published between 2000 and 2024. The keywords used were “Rheumatoid Arthritis,” “DMARDs,” “biologics,” and “JAK inhibitors.” We prioritized randomized controlled trials, meta-analyses, and clinical guidelines from EULAR and ACR.
Results: Methotrexate is still the mainstay of csDMARD therapy and effectively controls disease activity. JAK inhibitors like tofacitinib and baricitinib offer effective oral options with quick symptom relief. Biologic agents, including TNF inhibitors and non-TNF biologics (tocilizumab, rituximab), have improved outcomes for patients with hard-to-treat RA. Using combinations and starting aggressive therapies early increases remission rates. Safety issues, such as the risk of infection, liver toxicity, and heart events, require careful monitoring of patients.
Conclusion: Recent advances in DMARDs and biologics have changed how RA is managed, allowing for targeted and personalized treatments. A strategy focused on treating to target, which includes early intervention and the involvement of clinical pharmacists, is crucial for achieving optimal outcomes. Future developments in biosimilars and therapies guided by biomarkers promise even more improvements
Downloads
References
Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016;388(10055):2023-2038.
Alamanos Y, Drosos AA. Epidemiology of adult rheumatoid arthritis. Autoimmun Rev. 2005;4(3):130-136.
Cross M, Smith E, Hoy D, et al. The global burden of rheumatoid arthritis: estimates from the Global Burden of Disease 2010 study. Ann Rheum Dis. 2014;73(7):1316-1322.
McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med. 2011;365(23):2205-2219.
Firestein GS. Evolving concepts of rheumatoid arthritis. Nature. 2003;423(6937):356-361.
Kirwan JR. The effects of glucocorticoids on joint destruction in rheumatoid arthritis. N Engl J Med. 1995;333(3):142-146.
Weinblatt ME. Methotrexate in rheumatoid arthritis: a quarter century of development. Trans Am Clin Climatol Assoc. 2013;124:16-25.
Smolen JS, Landewé R, Bijlsma J, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological DMARDs: 2019 update. Ann Rheum Dis. 2020;79(6):685-699.
O’Shea JJ, Kontzias A, Yamaoka K, Tanaka Y, Laurence A. Janus kinase inhibitors in autoimmune diseases. Ann Rheum Dis. 2013;72 Suppl 2:ii111-5.
McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med. 2011;365(23):2205–2219.
Gregersen PK, Silver J, Winchester RJ. The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum. 1987;30(11):1205–1213.
Källberg H, Padyukov L, Plenge RM, et al. Gene–environment interaction between HLA-DRB1 shared epitope and smoking in anti–cyclic citrullinated peptide–positive rheumatoid arthritis: results from a population-based case–control study. Arthritis Rheum. 2007;56(6):1662–1669.
Firestein GS, McInnes IB. Immunopathogenesis of rheumatoid arthritis. Immunity. 2017;46(2):183–196.
van der Woude D, van der Helm-van Mil AHM. Update on the epidemiology, risk factors, and disease outcomes of rheumatoid arthritis. Best Pract Res Clin Rheumatol. 2018;32(2):174–187.
Schett G, Gravallese E. Bone erosion in rheumatoid arthritis: mechanisms, diagnosis and treatment. Nat Rev Rheumatol. 2012;8(11):656–664.
Bartok B, Firestein GS. Fibroblast-like synoviocytes: key effector cells in rheumatoid arthritis. Immunol Rev. 2010;233(1):233–255.
Smolen JS, Landewé R, Bijlsma J, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological DMARDs: 2019 update. Ann Rheum Dis. 2020;79(6):685–699.
Weinblatt ME. Methotrexate in rheumatoid arthritis: a quarter century of development. Trans Am Clin Climatol Assoc. 2013;124:16 25.
Cronstein BN. Low-dose methotrexate: a mainstay in the treatment of rheumatoid arthritis. Pharmacol Rev. 2005;57(2):163–172.
Visser K, Katchamart W, Loza E, et al. Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders. Ann Rheum Dis. 2009;68(7):1086–1093.
Ranganath VK, Maranian P, Elashoff DA, et al. Comorbidities are associated with poorer outcomes in community patients with rheumatoid arthritis. Rheumatology (Oxford). 2013;52(10):1809–1817.
O’Dell JR, Mikuls TR, Taylor TH, et al. Therapies for active rheumatoid arthritis after methotrexate failure. N Engl J Med. 2013;369(4):307–318.
van Ede AE, Laan RFJM, Rood MJ, et al. Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: a forty-eight-week, multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum. 2001;44(7):1515–1524.
Wallace DJ. The history of antimalarials. Lupus. 1996;5(Suppl 1):S2–S7.
Marmor MF, Kellner U, Lai TY, et al. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy. Ophthalmology. 2016;123(6):1386–1394.
Strand V, Cohen S, Schiff M, et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Arthritis Rheum. 1999;42(9):1870–1878.
Wiese MD, Boey W, Heffernan M, et al. Leflunomide in rheumatoid arthritis: recommendations for use. Intern Med J. 2012;42(12):1361–1369.
O’Dell JR. Therapeutic strategies for rheumatoid arthritis. N Engl J Med. 2004;350(25):2591–2602.
Singh JA, Furst DE, Bharat A, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of DMARDs and biologic agents in the treatment of RA. Arthritis Care Res (Hoboken). 2012;64(5):625–639.
O’Shea JJ, Kontzias A, Yamaoka K, Tanaka Y, Laurence A. Janus kinase inhibitors in autoimmune diseases. Ann Rheum Dis. 2013;72(Suppl 2):ii111–ii115.
van der Heijde D, Tanaka Y, Fleischmann R, et al. Tofacitinib in patients with rheumatoid arthritis: a meta-analysis. Clin Rheumatol. 2013;32(5):583–592.
Taylor PC, Keystone EC, van der Heijde D, et al. Baricitinib versus placebo or adalimumab in rheumatoid arthritis. N Engl J Med. 2017;376(7):652–662.
Fleischmann R, Pangan AL, Song IH, et al. Upadacitinib versus placebo or adalimumab in rheumatoid arthritis. Lancet. 2019;393(10188):2303–2311.
Schwartz DM, Kanno Y, Villarino A, Ward M, Gadina M, O’Shea JJ. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat Rev Drug Discov. 2017;16(12):843–862.
Smolen JS, Genovese MC, Takeuchi T, et al. Safety of baricitinib in patients with rheumatoid arthritis: an integrated analysis. Lancet Rheumatol. 2020;2(10):e553–e565.
Cohen S, Tanaka Y, Mariette X, et al. Long-term safety of tofacitinib up to 9.5 years: integrated analysis of the global clinical trial programme in rheumatoid arthritis. Ann Rheum Dis. 2020;79(7):1039–1046.
US FDA Drug Safety Communication. FDA warns about increased risk of blood clots and death with higher doses of tofacitinib in rheumatoid arthritis patients. [Internet]. 2019. Available from: https://www.fda.gov
Singh JA, Saag KG, Bridges SL Jr, et al. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol. 2016;68(1):1–26.
Feldmann M, Maini RN. Anti-TNF therapy, from rationale to standard of care: what lessons has it taught us? J Immunol. 2010;185(2):791–794.
Emery P, Breedveld FC, Hall S, et al. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active early rheumatoid arthritis. Arthritis Rheum. 2008;58(2):295–308.
Jones G, Sebba A, Gu J, et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis. Arthritis Rheum. 2010;62(4):1005–1015.
Edwards JC, Szczepanski L, Szechinski J, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med. 2004;350(25):2572–2581.
Genovese MC, Becker JC, Schiff M, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor α inhibition. N Engl J Med. 2005;353(11):1114–1123.
Singh JA, Cameron C, Noorbaloochi S, et al. Comparative effectiveness of biologics in rheumatoid arthritis: a network meta-analysis. Cochrane Database Syst Rev. 2020;5(5):CD012095.
O’Dell JR, Mikuls TR, Taylor TH, et al. Therapies for active rheumatoid arthritis after methotrexate failure. N Engl J Med. 2013;369(4):307–318.
Fleischmann R, Mysler E, Hall S, et al. Efficacy and safety of upadacitinib vs adalimumab in patients with rheumatoid arthritis. Arthritis Rheumatol. 2019;71(11):1788–1800.
van Vollenhoven RF, Emery P, Bingham CO, et al. Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up. Rheumatology (Oxford). 2020;59(6):1293–1301.
Curtis JR, Xie F, Chen L, et al. Real-world comparative risks of herpes zoster and serious infection in tofacitinib vs TNF inhibitors. Ann Rheum Dis. 2021;80(2):269–277.
Eades CE, Ferguson JS, O’Carroll RE. Public health roles for pharmacists in RA: A systematic review. Br J Clin Pharmacol. 2011;72(5):837–846
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
